Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Probiotics Antimicrob Proteins. 2022 Jun;14(3):486-500. doi: 10.1007/s12602-021-09817-0. Epub 2021 Jul 13.
Mucositis is one of the most strenuous side effects caused by chemotherapy drugs, such as 5-fluorouracil (5-FU), during the treatment of several types of cancers. The disease is so prevalent and aggressive that many patients cannot resist such symptoms. However, despite its frequency and clinical significance, there is no effective treatment to prevent or treat mucositis. Thus, the use of probiotics as an adjuvant for the treatment has gained prominence. In the present study, we evaluated the effectiveness of oral administration of the Antarctic strain of Rhodotorula mucilaginosa UFMGCB 18,377 as an alternative to minimize side effects of 5-FU-induced mucositis in mice. Body weight, food consumption, stool consistency, and presence of blood in the feces were assessed daily in mice orally treated or not with the yeast and submitted or not to experimental mucositis. Blood, bones, and intestinal tissues and fluid were used to determine intestinal permeability and immunological, microbiological, and histopathological parameters. Treatment with R. mucilaginosa UFMGCB 18,377 was able to decrease clinical signs of the disease, such as reduction of food intake and body weight loss, and also decreased the number of intestinal enterobacteria and intestinal length shortening. Additionally, treatment was able to decrease the levels of MPO and EPO activities and inflammatory infiltrates, as well as the histopathological lesions characteristic of mucositis in the jejunum and ileum. Results of the present study showed that the oral administration of R. mucilaginosa UFMGCB 18,377 protected mice against mucositis induced by 5-FU.
黏膜炎是癌症治疗过程中使用的多种化疗药物（如 5-氟尿嘧啶[5-FU]）引起的最严重的副作用之一。这种疾病非常普遍且具有侵袭性，以至于许多患者无法抵抗这些症状。然而，尽管其发病率高且具有临床意义，但目前尚无有效的治疗方法来预防或治疗黏膜炎。因此，使用益生菌作为辅助治疗方法引起了关注。在本研究中，我们评估了口服南极红酵母 UFMGCB 18,377 对减轻 5-FU 诱导的黏膜炎小鼠副作用的有效性，作为一种替代方法。我们每天评估口服酵母或未口服酵母且接受或未接受实验性黏膜炎的小鼠的体重、食物消耗、粪便稠度和粪便中是否有血。血液、骨骼和肠道组织和液体用于确定肠道通透性以及免疫、微生物和组织病理学参数。红酵母 UFMGCB 18,377 的治疗能够减少疾病的临床症状，如减少食物摄入和体重减轻，并且还减少了肠道肠杆菌的数量和肠道缩短的长度。此外，治疗能够降低 MPO 和 EPO 活性和炎症浸润的水平，以及回肠和空肠中特征性的黏膜炎组织病理学病变。本研究结果表明，口服红酵母 UFMGCB 18,377 可保护小鼠免受 5-FU 诱导的黏膜炎。
